Benzinga | May 21, 2021 08:03AM EDT

Exact Sciences Highlights Data Being Featured At 2021 Digestive Disease Week May 21-23

Exact Sciences Corp. (NASDAQ:EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week(r) (DDW(r)) virtual annual meeting, taking place May 21-23.

Notably, the poster shares data that incorporate real-world patient adherence rates into a colorectal cancer (CRC) microsimulation model. The data showed that Cologuard(r) (mt-sDNA) was cost effective and provided the greatest reduction in CRC incidence and mortality versus annual fecal immunochemical test (FIT) and annual fecal occult blood test (FOBT) in a representative Medicare population.

Additionally, the oral presentation reports data from the New Hampshire Colonoscopy Registry to compare FIT and Cologuard outcomes in clinical practice. In follow-up colonoscopies performed after a positive stool test result, Cologuard was more likely to predict neoplasia than FIT, largely due to an increased detection of serrated polyps.

Colorectal cancer is the second deadliest cancer impacting both men and women in the U.S. It's also preventable if caught in early stages when it is more treatable.i The disease has been on the rise in younger adults and approximately 44 million average-risk people in the United States remain unscreened.ii

The abstracts are now available on the DDW website. Included below are titles, abstract numbers, and a summary of each abstract.